Epigenetics for Drug Discovery: Dissecting the Effect of High Antipsychotic Dosage and D2 Blockage on Peripheral DNA Methylation

Abstract

Introduction The relationship between genetic polymorphisms of antipsychotic drug-metabolizing agents and drug receptors has been often investigated. DNA methylation is a form of epigenetic modification that regulates gene expression. Few studies have analyzed the relationship between genome-wide methylation patterns and antipsychotic dosage. The primary aim of this pilot study was to investigate the association between antipsychotic dosage and genome-wide DNA methylation in patients with schizophrenia (SCZ).

Methods Current dosage of antipsychotic medications was assessed in 136 patients with SCZ. Dosage was standardized using three different methods: chlorpromazine equivalent dose (CPZe), defined daily dose (DDD), and percentage of Lexicomp maximum dose (PM%). DNA methylation was measured in white blood cells. Antipsychotic dosage was the primary outcome variable in a model, including genome-wide methylation status as the main predictor.

Results This study did not show any association between DNA methylation and dosage variation for CPZe, PM%, and DDD. However, the probe cg271403389 was consistently associated with antipsychotic dosage across the three standardization methods. When looking at the genomic location of the most significant probes, we found that 15% were intergenic, 23% were in the distal promoter, 9% in the 3′untranslated region, 32% in the gene body, 3% in the 5′ untranslated region, 15% in the proximal promoter, and 3% in the first exon.

Discussion This study shows the importance of investigating the relationship between DNA methylation and optimal antipsychotic dosage to personalize treatment in SCZ. Future studies require larger prescription databases to build on the results of this analysis.

Key words

pharmacogenetics - personalized medicine - DNA methylation - epigenetics - CPZe

Publikationsverlauf

Eingereicht: 04. August 2021
Eingereicht: 11. Mai 2021

Angenommen: 30. Januar 2022

Artikel online veröffentlicht:
28. April 2022

• References

• 1 Polese D, Fornaro M, Palermo M. et al. Treatment-resistant to antipsychotics: A resistance to everything? Psychotherapy in treatment-resistant schizophrenia and nonaffective psychosis: A 25-year systematic review and exploratory meta-analysis. Front Psychiatry 2019; 10: 210
• 2 Patel KR, Cherian J, Gohil K. et al. Schizophrenia: Overview and treatment options. P T 2014; 39: 638-645
• 3 Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978; 135: 165-173
• 4 Dazzan P, Morgan KD, Orr KG. et al. The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study. Brain 2004; 127: 143-153
• 5 Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-246
• 6 Leo RJ, Regno PD. Atypical antipsychotic use in the treatment of psychosis in primary care. Prim Care Companion J Clin Psychiatry 2000; 2: 194-204
• 7 Dazzan P, Morgan KD, Orr K. et al. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: The AESOP study. Neuropsychopharmacology 2005; 30: 765-774
• 8 McClay JL, Adkins DE, Aberg K. et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2011; 16: 76-85
• 9 Aapola U, Kawasaki K, Scott HS. et al. Isolation and initial characterization of a novel zinc finger gene, DNMT3L, on 21q22.3, related to the cytosine-5-methyltransferase 3 gene family. Genomics 2000; 65: 293-298
• 10 Zannas AS, West AE. Epigenetics and the regulation of stress vulnerability and resilience. Neuroscience 2014; 264: 157-170
• 11 Bock C, Walter J, Paulsen M. et al. CpG island mapping by epigenome prediction. PLoS Comput Biol 2007; 3: e110
• 12 Greenberg MVC, Bourc’his D. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol 2019; 20: 590-607
• 13 Misiak B, Szmida E, Karpinski P. et al. Lower LINE-1 methylation in first-episode schizophrenia patients with the history of childhood trauma. Epigenomics 2015; 7: 1275-1285
• 14 Bani-Fatemi A, Adanty C, Dai N. et al. Genome-wide methylation association with current suicidal ideation in schizophrenia. J Neural Transm (Vienna) 2020; 127: 1315-1322
• 15 Bani-Fatemi A, Jeremian R, Wang KZ. et al. Epigenome-wide association study of suicide attempt in schizophrenia. J Psychiatr Res 2018; 104: 192-197
• 16 First MB WJ, Karg RS, Spitzer RL. Structured clinical interview for DSM-5 – Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). Arlington, VA: American Psychiatric Association; 2015
• 17 WHO. Guidelines for ATC classification and DDD assignment 2021, Collaborating Centre for Drug Statistics Methodology. 2021
• 18 Gardner DM, Murphy AL, O’Donnell H. et al. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686-693
• 19 Lahiri DK, Nurnberger JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444
• 20 Bibikova M, Barnes B, Tsan C. et al. High density DNA methylation array with single CpG site resolution. Genomics 2011; 98: 288-295
• 21 Aryee MJ, Jaffe AE, Corrada-Bravo H. et al. Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 2014; 30: 1363-1369
• 22 Saffari A, Silver MJ, Zavattari P. et al. Estimation of a significance threshold for epigenome-wide association studies. Genet Epidemiol 2018; 42: 20-33
• 23 Jaffe AE, Irizarry RA. Accounting for cellular heterogeneity is critical in epigenome-wide association studies. Genome Biol 2014; 15: R 31
• 24 Ritchie ME, Phipson B, Wu D. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43: e47
• 25 Jaffe AE, Murakami P, Lee H. et al. Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol 2012; 41: 200-209
• 26 Li D, Xie Z, Pape ML. et al. An evaluation of statistical methods for DNA methylation microarray data analysis. BMC Bioinformatics 2015; 16: 217
• 27 Maksimovic J, Phipson B, Oshlack A. A cross-package bioconductor workflow for analysing methylation array data. F1000Res 2016; 5: 1281
• 28 Benjamini Y, Drai D, Elmer G. et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125: 279-284
• 29 Ventham NT, Kennedy NA, Adams AT. et al. Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. Nat Commun 2016; 7: 13507
• 30 Steiger H, Booij L, Kahan E. et al. A longitudinal, epigenome-wide study of DNA methylation in anorexia nervosa: results in actively ill, partially weight-restored, long-term remitted and non-eating-disordered women. J Psychiatry Neurosci 2019; 44: 205-213
• 31 Heiskanen T, Niskanen L, Lyytikainen R. et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64: 575-579